COMMUNIQUÉS West-GlobeNewswire

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference
03/02/2026
SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
03/02/2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry [...]
Berry Street Named to 2026 New York Digital Health 100 List
03/02/2026
Digital Health New York recognizes nutrition therapy platform’s innovative approach to evidence-based nutrition care NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Berry Street , a nutrition therapy platform, today [...]
MediGlow Utility (MGU) Releases a Technical Exploration Framework for Digital Identity and Privacy Protection
03/02/2026
MediGlow Utility (MGU) Proposes a Technical Practice Direction for Medical Data Management Based on Blockchain Technology New York, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Recently, MediGlow Utility (MGU) announced the [...]
Byonyks X1: Revolutionizing Dialysis - Now FDA Cleared and Planning to start Patients in the U.S.
03/02/2026
A major regulatory milestone positioning Byonyks as a new entrant in home-based renal care CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Byonyks, headquartered in Chicago, Illinois, has received U.S. FDA 510(k) clearance [...]
Socrates Health Solutions Announces Advances in Proprietary Non-Invasive Glucose Monitoring Technology; Shareholders Include NFL Players Association and OneTeam Partners
03/02/2026
DALLAS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Socrates Health Solutions (“Socrates”), advancing a purpose-led mission to pursue a better feedback loop for health issues spanning diabetes management, broader health [...]
Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025
03/02/2026
Bagsværd, Denmark 3 February 2026 - Financial report for the period 1 January 2025 to 31 December 2025 Operating profit decreased by 1% in Danish kroner and increased by 6% at constant exchange rates (CER) to DKK 127.7 [...]
RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy
03/02/2026
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic Inflammatory Myopathy [...]
Novo Nordisk releases 2026 sales and operating profit outlook
03/02/2026
Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. [...]
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
03/02/2026
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Neomorph, Inc. , a biotechnology company pioneering molecular glue [...]
Beghou Names Meredith Ressi as President and Chief Growth Officer
03/02/2026
Appointment reflects Beghou’s focus on scaling intelligently with integrated teams and technology to support clients throughout their commercialization journey EVANSTON, Ill., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Beghou , [...]
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026
This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Department of Education Proposal Still Excludes Nursing from “Professional Degree” Definition
03/02/2026
ANA urges nurses, patients, and the public to submit comments demanding nursing be added SILVER SPRING, MD, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The American Nurses Association (ANA) is deeply concerned that the U.S. [...]
HFMA’s Vitalic Health to gather more than 50 payers, providers and tech leaders to address rising claim denials
03/02/2026
CHICAGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association’s Vitalic Health announced today it will convene more than 50 payers, providers and tech companies to simplify and standardize [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
03/02/2026
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non- [...]
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
03/02/2026
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41 st Asia-Pacific Academy of Ophthalmology (APAO [...]
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
03/02/2026
Mr. Pujols brings more than 30 years of technical operations expertise to role, scaling commercial manufacturing for CAR T-cell therapies and complex biologics, as Kyverna advances towards launch of miv-cel EMERYVILLE, [...]
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]

Pages